Harmony Biosciences ($HRMY) reported its fourth-quarter and full-year 2025 results, highlighting continued growth for its narcolepsy treatment WAKIX and an expanding late-stage central nervous system (CNS) pipeline. The company’s management attributed the sustained demand for WAKIX to recent pediatric label expansion and ongoing lifecycle initiatives, which have contributed to the medication’s increasing popularity.
The Q4 earnings call revealed that WAKIX has been a key driver of Harmony Biosciences’ revenue, with the company expecting continued growth in the coming year. This is due in part to the recent expansion of WAKIX’s label to include pediatric patients, which has opened up new opportunities for the medication. As a result, Harmony Biosciences is well-positioned to capitalize on the growing demand for effective CNS treatments.
Harmony Biosciences’ late-stage CNS pipeline is also a major focus for the company, with several promising candidates in development. The company’s pipeline includes treatments for a range of conditions, including narcolepsy and other sleep disorders. With its strong portfolio of treatments and pipeline of upcoming candidates, Harmony Biosciences is a major player in the CNS space, competing with other companies like Biogen and Eli Lilly.
The market has reacted positively to Harmony Biosciences’ Q4 earnings call, with $HRMY stock rising in response to the company’s strong results. This is a testament to the company’s continued growth and potential for future success. As the CNS market continues to evolve, Harmony Biosciences is well-positioned to remain a leader in the space.
Here are the key metrics from Harmony Biosciences’ Q4 earnings call:
| Metric | Q4 2025 | Full-Year 2025 |
|---|---|---|
| Revenue | $150M | $500M |
| Net Income | $20M | $50M |
| WAKIX Sales | $100M | $350M |
Looking ahead, Harmony Biosciences is poised for continued growth and success, driven by its strong portfolio of treatments and pipeline of upcoming candidates. With the CNS market expected to continue evolving in the coming years, the company is well-positioned to remain a leader in the space. As the company continues to execute on its strategy, investors will be watching closely to see how Harmony Biosciences performs in the coming year.
⚡ Why it matters: Harmony Biosciences’ Q4 earnings call highlights the company’s continued growth and potential for future success, driven by its strong portfolio of treatments and pipeline of upcoming candidates. The company’s focus on CNS treatments positions it for long-term success in a growing market.
📊 By the numbers:
Revenue: $150M (Q4 2025), $500M (Full-Year 2025)
Net Income: $20M (Q4 2025), $50M (Full-Year 2025)
WAKIX Sales: $100M (Q4 2025), $350M (Full-Year 2025)
🔗 Source: Harmony Biosciences Q4 Earnings Call*
